Key clinical point: Results from the SORCE trial confirm that sorafenib should not be used as adjuvant therapy for patients with resected renal cell carcinoma who have an intermediate or high risk of recurrence.

Major finding: The median disease-free survival was not reached whether patients received 3 years of sorafenib or placebo (hazard ratio, 1.01; P = .95).

Study details: A phase 3 trial of 1,711 patients randomized to 3 years of placebo, 1 year of sorafenib followed by 2 years of placebo, or 3 years of sorafenib.

Disclosures: The trial was supported by Bayer, Cancer Research UK, the Medical Research Council, University College London, Cancer Australia, and the Australian National Health and Medical Research Council. The authors disclosed relationships with many companies.